Mucinous Ovarian Carcinoma
- Morice, Philippe M.D., Ph.D.
- Gouy, Sebastien M.D., Ph.D.
- Leary, Alexandra M.D., Ph.D.
From the Departments of Gynecological Surgery and Medical Oncology (P.M., S.G., A.L.), INSERM Unit 981 (A.L.), and INSERM Unit 10-30 (P.M.), Gustave Roussy Cancer Campus, Villejuif, and University Paris-Sud (Paris XI), Le Kremlin Bicêtre (P.M.) — both in France.
Dan L. Longo, M.D., Editor
Address reprint requests to Dr. Morice at the Department of Gynecological Surgery, Gustave Roussy Cancer Campus, 94805 Villejuif CEDEX, France, or at [email protected].
Dr. Morice reports receiving advisory board fees from Roche, lecture fees from Johnson & Johnson, and fees for participating on a board from Clovis; Dr. Gouy, receiving consulting fees from Roche; and Dr. Leary, receiving fees for serving as chief investigator or principal investigator on clinical trials, travel support paid to her institution, and advisory board fees from AstraZeneca; fees for serving as principal investigator on clinical trials, travel support paid to her institution, and advisory board fees from Clovis; travel support and advisory board fees from Tesaro; advisory board fees from Gridstone, Seattle Genetics, and Biocad; grant support paid to her institution from Merus and Inivata; fees for serving as chief investigator or principal investigator on a clinical trial paid to her institution from Roche, Pfizer, MSD, BMS, and Pharmamar; and grant support paid to her institution, fees for serving as chief investigator on a clinical trial, and advisory board fees from GamaMabs. No other potential conflict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
We thank Catherine Genestie, Patricia Pautier, and Jean Charles Soria for their comments and suggestions regarding an earlier draft of the manuscript.
